Physician profile
Brian Chen
NPI 1730557794
$1,415.10
in general payments reported to CMS, 2019-2025
15 companies · $31.98 in 2025
The $31.98 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $174 · 2023: $566 · 2024: $23.46 · 2025: $31.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $446.04 | 2022-2023 | Apretude, Rukobia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.22 | 2021 | |
| Gilead Sciences, INC. | $130.43 | 2023 | |
| Boston Scientific Corporation | $101.20 | 2021 | |
| Emd Serono, INC. | $89.88 | 2023 | Serostim |
| Pfizer INC. | $62.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $58.44 | 2021 | |
| Redhill Biopharma INC. | $50.41 | 2021 | |
| Glaxosmithkline, LLC. | $31.98 | 2025 | Nucala |
| Collegium Pharmaceutical, INC. | $30.39 | 2021 | |
| Merck Sharp & Dohme LLC | $29.50 | 2023 | Delstrigo, Pifeltro |
| Abbott Laboratories | $23.46 | 2024 | Xience Skypoint |
| Janssen Biotech, INC. | $21.79 | 2022 | |
| Theratechnologies INC. | $21.48 | 2023 | Trogarzo, Egrifta |
| Arbor Pharmaceuticals, INC. | $16.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.